Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Laine1on Jul 28, 2009 9:21am
335 Views
Post# 16171113

RE: RE: RE: Beware Of Hype Thou Even Big Pharma Ca

RE: RE: RE: Beware Of Hype Thou Even Big Pharma Ca

I noticed - I had to read the release a few times to get a good grasp of what they were announcing. Left me with the "so what" syndrome. I am not convinced that a NR is the best place to "recap" the information that was already released in previous NR. We can read, we got it the first time....if there is no news, don't try and create some out of OLD news. It just comes off looking unprofessional. As for the meta-analysis - ditto.

 

I work in the industry and I have met some some brilliant scientists - they tend to not be so brilliant at public relations. I grant respect to both professions but they ARE two different skill sets.

Yes, some would like only hype - but if SSS was more serious about their PR there be no need for hype. Your term "cocky" just struck a nerve with me.  Your vent is justified.



 

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse